Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its late-stage candidate for metabolic dysfunction-associated steatohepatitis (MASH). The $14.50-per-share deal ...
The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their clinical trials. The agency gave a green light to the AI-Based Histologic ...
Unjumble Michigan politics with MichMash. Each week, Cheyna Roth, Zach Gorchow and Alethia Kasben interview lawmakers and politicos, and unpack the statewide issues that affect you. MichMash is ...
The unlikely friendship of a boy, a mole, a fox and a horse traveling together in the boy's search for home.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback